Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Novartis acquires SNV4818 from Synnovation in $3bn deal to reclaim ground in mutant PI3Ka breast cancer space
Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.
Why Gilead Sciences’ Arcellx acquisition reshapes the competitive dynamics of BCMA CAR T therapy
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.